NEW NANOTHERAPY RESEARCH FOR INFLAMMATORY BOWEL DISEASES
THE NEW DEAL CONCEPT COULD REVOLUTIONIZE IBD THERAPIES FOR THE GREAT BENEFIT OF PATIENTS AND EUROPEAN HEALTHCARE SYSTEMS.
- Dr. Fabrice NAVARRO, New Deal Project Coordinator
THE PROJECT GOALS
THE PROJECT GOALS
The NEW DEAL project aims to develop a highly selective and local therapy with an improved efficacy and safety profile for IBD patients. This treatment might be an alternative to the existing therapies.
Design and validate a radically improved IBD therapy that specifically targets JAK1 / JAK3 inhibition by means of siRNA and RNAi interference.
Develop advanced technologies for delivering siJAK1 / siJAK3 locally to the inflamed gut
Promote the clinical translation and the future industrial transfer of this new clinical product for IBD therapy.
THE PROJECT NEWS
November New Deal Reads
Patient involvement in clinical research: why, when and how. Sacristán JA. Et al. Patient preference and adherence, volume [...]
IBD & Tea: Building trust in new treatments & understanding clinical trials
Tina Aswani Omprakash is an award-winning blogger, speaker and patient opinion leader who advocates for chronic illnesses and [...]
Small drugs – Big considerations: How New Deal researchers are overcoming the challenges of scaling-up a potential IBD nanomedicine
A great chef could create an outstanding dish that revolutionizes cuisine – every time they prepare the recipe [...]
October New Deal Reads
Extracellular Vesicles With Possible Roles in Gut Intestinal Tract Homeostasis and IBD. Chang, X. et al. Mediators of [...]
THE PROJECT PARTNERS
THE PROJECT PARTNERS
